$ARDX News

Ardelyx Presents Real-World Data at ASN Kidney Week 2026 Showing Serum Phosphate Reductions Following XPHOZAH® (tenapanor) Initiation With or Without Phosphate Binders

Ardelyx Reports Real-World Phosphate Reductions With XPHOZAH Across Phosphate Binder Groups In Dialysis Patients, Presented At The ASN Kidney Week 2026

Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026

Ardelyx Presents Real-World Data at ACG 2026 Showing Reduced Healthcare Resource Utilization Following IBSRELA® Initiation in Adults with IBS-C

Ardelyx Presents Real-World Data Showing Significant Reduction In GI-Related Healthcare Resource Utilization After IBSRELA Initiation, At ACG 2026 Annual Meeting

Ardelyx to Present New Data on Hyperphosphatemia Management at ASN Kidney Week 2026

Ardelyx Earns Multiple Honors at the 2026 PM360 Trailblazer Awards

Ardelyx Targets $500M Revenue This Year, Profitability by 2027

Ardelyx Q2 2026 Earnings Call Transcript

Ardelyx, Inc. (ARDX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Hyperphosphatemia Market Insight, Epidemiology, and Market Forecast to 2036 Now Available — See Which Novel Mechanism Could Unseat Sevelamer as Phosphate Binders Face a Pill-Burden Reckoning

Ardelyx to Participate in Upcoming Investor Conferences

Ardelyx (ARDX) Cuts Guidance On Payer Hurdles As Fair Value Debate Heats Up

Wedbush Reiterates Outperform on Ardelyx, Maintains $9 Price Target

Wedbush Reiterates Outperform on Ardelyx, Maintains $9 Price Target

Piper Sandler Maintains Overweight on Ardelyx, Lowers Price Target to $15

Ardelyx (ARDX) Q2 2026 Earnings Call Transcript

Ardelyx Q2: Strong Demand, But Payer Friction Clouds The Story

Ardelyx (ARDX) Is Down 19.7% After Raising IBSRELA Revenue Guidance And Narrowing Losses

Citigroup Maintains Buy on Ardelyx, Lowers Price Target to $11